Eric Lefkofsky: An Individual with a Vision to do Something Unique for Medical Sector

Tempus is a unique firm or an online portal that founded with hope as a startup program cancer fighting, and Groupon founded it. The founder of Groupon is Eric Lefkofsky, and the reason behind Tempus is to assist doctors or scientist of Chicago University to have a centralized database that will help them to save the data online without having to worry about repeating same procedures and methods time and again. This unique idea comes into the mind of Eric, and then he discussed that few of his fellows and they founded Tempus. At first, the circle of Tempus limited, but Eric is planning to turn Tempus into a global solution so that everyone can take benefit of it.

Due to the services that Tempus is offering for the Chicago and Cancer Treatment, Medicine department of the same university announced to become an official member with Tempus to boost the process to help to find a cure for different life threatening diseases. So, that can also play their role in finding a cure for the life-threading disease. Professionals at Tempus along with Eric said that they would analyze data from over one thousand patients who has breast cancer to help researchers in discovering the uncover patterns which may predict how patients are going respond to a particular treatment. That would be a groundbreaking discovery if Tempus would have done that.

Mr. Eric is quite certain that with his team of experts who are working being Tempus, they are soon going to find the pattern in patients who are suffering the same life-threatening diseases. And as soon as they can find it, it would help the doctor to suggest patients a more effective treatment to control or cure of that disease. The goal of Tempus is that, by the time, this data is going to assist in leading to improved patient outcomes and better treatment as mentioned earlier in this post. Experts of Tempus are using genomic sequencing along with machine learning technology to assist medical professionals to make, real-time treatment decisions so that would be able to suggest most effective treatment to the client.

Eric Lefkofsky on Twitter.

Dr. Clay Siegal And Seattle Genetics: Leaders In The Fight Against Cancer

Biotechnology company Seattle Genetics has developed a reputation worldwide as a company that is creating breakthrough cancer therapies. Seattle Genetics has earned that reputation because of the tireless work of Dr. Clay Siegal and the caring, experienced staff at the facility. The company is known for developing and commercializing some of the most effective, innovative, antibody-based therapies used in the treatment of cancer today. The success of their antibody-drug conjugate technology has made them an industry leader in the fight against many forms of cancer.

 

Their ADC technology is one of the most effective cancer treatments seen in decades. It uses monoclonal antibodies to kill cancer cells and enhance antitumor activity without doing damage to the surrounding cells and tissue. This technology is currently licensed for use in 60 countries. Seattle Genetics also has a wide range of other cancer healing therapies in its deep product pipeline. Company president and CEO Dr. Clay Siegal has played a major role in the company’s success. Not only has he encouraged rigorous research and innovative drug development practices, Dr. Siegal has also raised millions in funding for the company.

 

An experienced scientist, Dr. Clay Siegal is very knowledgeable and talented and has a passion for his work. He has been involved with some of the leading companies involved in the fight against cancer. They include the National Institutes of Health,

Ultragenyx Pharmaceutical, Alder Biopharmaceuticals Inc. and Mirna Therapeutics, Inc. Dr. Clay Siegal has a B.S. in Zoology from University of Maryland and a Ph.D in Genetics from George Washington University and has been involved in cancer research and targeted cancer therapies for decades. His work is driven by a focus on helping patients.

 

Founded in 1998 and headquartered in Bothell, Washington, Seattle Genetics has partnered with companies worldwide to get their cancer fighting treatments into the hands and bodies of as many cancer patients as possible. Currently Seattle Genetics licenses their ADC technology to Genentech, Pfizer, AbbVie and GlaxoSmithKline to help patients worldwide. Dr. Clay Siegal has earned numerous awards for his work with Seattle Genetics. They include being voted Entrepreneur of the Year.

 

Sources:

http://www.pegsummit.com/uploadedFiles/PEGS/Agenda/15/PEGS-Interview-Siegall.pdf

http://www.mirnatherapeutics.com/pdfs/releases/2013%200130%20Mirna%20Siegall%20BOD.pdf